Further, gallic acid is known to bind to vascular endothelial growth factor 2 (VEGFR2), which is expressed in tumor vasculature, including GL261 gliomas, but not in healthy vessels, thus enabling tumor vessel targeting and the systemic administration of the nanoclovers. This evidence concerns the gene KDR and neoplasm.